WiCON | Pharma China (Web Edition)

ONLINE ENQUIRY

WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com

WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com

High Return Rate: Are Chinese Innovative Drugs Facing a "Breakup" Crisis in Ov... Analysis of Booming License-Out Deals Reveals a Concerning Trend of Terminated Collaborations for Chinese Pharmaceutical Companies, according to a recent feature article ...
(4/29/2025)

China's Clinical Trial Boom (Asimov Press) (5/22/2025)

'China's Ozempic' may vie with Eli Lilly, Novo... (5/20/2025)

How Trump's Proposed Price Cuts Could Hurt Chi... (5/20/2025)

US Tariffs on Pharmaceuticals Could Hit Chines... (5/16/2025)

SMEI: China's Pharmaceutical Industry Seeks St... (5/16/2025)

Trump's Drug Pricing and the US-China Trade De... (5/12/2025)

China Still Go-To Source for New Drugs Despite... (5/9/2025)

Redefining Translational Research and China's ... (5/8/2025)

China Introduces A New Regulatory Data Protect... (5/5/2025)

Pharma's Crossroads: U.S. Investment Surges Un... (5/1/2025)

High Return Rate: Are Chinese Innovative Drugs... (4/29/2025)

China Aims for Significant Pharma Industry Dig... (4/26/2025)

Recent Official and Executive Moves (5/31/2025) China Approves First Homegrown Nine-Vale... (5/31/2025) Cancer Vaccine Trials in China and the U... (5/31/2025) China's Breakthru Weight-Loss Drug Makes... (5/31/2025) Hengrui Medicine Gains NMPA Approval for... (5/31/2025) Hansoh Receives NMPA Approval for Clinic... (5/31/2025) China Grants Conditional Approval to Zym... (5/31/2025) NMPA Issues New Regulations on Experimen... (5/31/2025) NMPA Reopens Comment on Draft Announceme... (5/31/2025) CSPC Eyes $5B in Licensing Deals for EGF... (5/31/2025) Astellas Enters Exclusive License Agreem... (5/31/2025) Ivonescimab Hits Key Milestone in Phase ... (5/31/2025) Former CFDA Commissioner Bi Jingquan Un... (5/31/2025) First Patient Dosed in YK012 Trial -The ... (5/29/2025) CDE Solicits Comments on Draft Technica... (5/29/2025) CDE Issues Guideline on Production Site ... (5/29/2025) CDE Launches “Starlight Plan” to Encou... (5/29/2025) CDE Issues Guideline on Safety Assessmen... (5/29/2025)

China's Hospital Drug Market Shows Slight Growth in 202... China Unveils Ambitious Plan to Boost Health-Related Co... Chinese VMS OTC Market Growth Slowed to 2.7% in 2024 Newish Tech Secures Series B Financing to Advance Next-... China's Retail Pharmacy Market Reaches CNY 574 Billion ...

Astellas Enters Exclusive License Agreement with Evopoi... CSPC Eyes $5B in Licensing Deals for EGFR-ADC and Innov... Livzon Acquires Majority Stake in Vietnam's Imexpharm f... AusperBio Secures $50M in Series B+ Financing Novartis Broadens Alliance with Shanghai Pharma to Incl...

NMPA Reopens Comment on Draft Announcement for Strength... NMPA Issues New Regulations on Experimental Research of... CDE Issues Guideline on Safety Assessment and Reporting... CDE Launches “Starlight Plan” to Encourage Pediatric ... CDE Issues Guideline on Production Site Change Research...

China Expands Geriatric Services at Major Hospitals as ... China's BMI Fund Reports Big Surplus in Q1/2025 China's Public Hospitals Grapple with Mounting Debt Ami... Dementia Cases Surge in China at an Unprecedented Rate NHC Ministers Meet with Top Pharma MNC Executives

AstraZeneca Faces Escalating Legal Challenges in China ... BeiGene Secures Key Patent Victory in Brukinsa Dispute ... State Council Approves Draft Medical Security Law, Stre... Novo Nordisk Sues KBP Biosciences for $830 Million Over... State Council Releases Final Antitrust Guidelines for t...

FDA Issues Warning Letters to Two Chinese API Manufactu... Implications of China's Growing Influence in Global Pha... FDA Issues Warning to Tianjin Darentang for Manufacturi... Shanghai Pharma Considers API Partnerships with Indian ... Aurobindo Challenges China in the Global Penicillin G M...

Ivonescimab Hits Key Milestone in Phase III HARMONi Tri... China Grants Conditional Approval to Zymeworks' Zanidat... Hansoh Receives NMPA Approval for Clinical Trials of Th... Hengrui Medicine Gains NMPA Approval for Three New Canc... China's Breakthru Weight-Loss Drug Makes Landmark Debut...

BioAtla and BeiGene Revise Global Deal for Novel Condit... Pfizer to Absorb Mylan, Creating Global Generic Powerho... PhRMA Calls for Trade Deals That Force Countries to Pay... IQVIA: Global Pharma to Grow Slower in the Next Five Ye... Pfizer and GSK Announce JV to Create a Global Consumer ...

Former CFDA Commissioner Bi Jingquan Under Investigati... Recent Official and Executive Moves Recent Executive Moves Recent Executive Moves Recent Executive Moves

China Introduces Plan for Pudong New Area's Pilot Compr... Upcoming Event: 2023 Pharma CI USA Conference & Exhibit... Upcoming Event: 15th Annual Pharma Market Research Conf... Upcoming Event: 6th International Conference on Emergin... Upcoming Event: PHARM Connect Congress

Pharma China is the most influential English media and source of business intelligence covering the Chinese pharmaceutical and biopharmaceutical sector...

WiCON has been helping international healthcare companies succeed in China and other Asian markets since 1991. We advise our clients on every stage of their China and Asian business. We worked with clients in many regions of the world...

2023 Order Form + Product Descripti... WiCON Publishes the China Pharmaceu... WiCON Publishes the China Pharmaceu... WiCON Publishes the China Pharmaceu... WiCON Publishes the China Pharmaceu...